IL1B and atherosclerosis: Although neutralizing IL-1β with the canakinumab antibody (at a dose of 150 mg every three months) improved cardiovascular events related to atherosclerosis, a major impediment in admitting this compound as a therapy are the undefined strict criteria for eligibility as the study revealed substantial side effects of the treatment [11,24,43].